Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.50 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4565980 | 0.84 | HPGD (0.44) | POLBHPGDCYP2D6CYP2C9TSHR | |
| SCHEMBL12727080 | 0.81 | PDGFRA (0.58) | CDK2 | |
| SCHEMBL1590850 | 0.81 | HPGD (0.46) | NPC1HPGDTNKSGRM5CDK2 | |
| SCHEMBL1590820 | 0.81 | PDGFRA (0.58) | CDK2 | |
| SCHEMBL6015440 | 0.80 | YTHDC1 (0.52) | YTHDC1CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL1590837 | 0.79 | MCHR1 (0.41) | HPGDTNKS | |
| SCHEMBL1590959 | 0.76 | GRM5 (0.49) | NPC1HPGDTNKSGRM5ALDH1A1 | |
| SCHEMBL1592216 | 0.75 | CYP2D6 (0.44) | NPC1POLBCDK5CDK5R1YTHDC1 | |
| SCHEMBL22587406 | 0.74 | CYP2D6 (0.55) | NPC1POLBCDK5CDK5R1YTHDC1 | |
| SCHEMBL3585775 | 0.73 | CDK1 (0.54) | CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092491-A1 | Compounds and Compositions as Inhibitors of Receptor Tyrosine Kinase Activity | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092491-A1 | Compounds and Compositions as Inhibitors of Receptor Tyrosine Kinase Activity | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092491-A1 | Compounds and Compositions as Inhibitors of Receptor Tyrosine Kinase Activity | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| EP-2124954-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008094737-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2008-08-07 | — | — | WO | disclosed |
| EP-1656378-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF RECEPTOR TYROSINE KINASE ACTIVITY | IRM LLC (BM) | 2006-05-17 | — | — | EP | disclosed |
| US-20050124637-A1 | Compounds and compositions as inhibitors of receptor tyrosine kinase activity | IRM LLC (BM) | 2005-06-09 | — | — | US | disclosed |
| WO-2005016528-A2 | 6-SUBSTITUTED ANILINO PURINES AS RTK INHIBITORS | IRM LLC (BM) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124637-A1 | Compounds and compositions as inhibitors of receptor tyrosine kinase activity | BMX, LCK, FYN | NPC1 3621/4885POLB 3364/4885CDK5 246/4885 |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | ADK, PNP, DCK | NPC1 2011/4885POLB 896/4885CDK5 333/4885 |
| US-20110092491-A1 | Compounds and Compositions as Inhibitors of Receptor Tyrosine Kinase Activity | BMX, LCK, FYN | NPC1 3621/4885POLB 3364/4885CDK5 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.